Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19805
- Registration Number
- NCT02242331
Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 440
- Registration Number
- NCT02242318
Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension
Phase 4
Terminated
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02242812
Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo via the grey HandiHaler®Drug: Placebo via the blue HandiHaler®
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 121
- Registration Number
- NCT02242266
Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 111
- Registration Number
- NCT02242227
Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14553
- Registration Number
- NCT02242357
TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or Older
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3320
- Registration Number
- NCT02242877
Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 97
- Registration Number
- NCT02242253
Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8148
- Registration Number
- NCT02242825
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2018-11-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 128
- Registration Number
- NCT02240693
- Locations
- 🇩🇪
emovis GmbH, Berlin, Germany
🇫🇷HOP Jean Bernard, Géria, Poitiers, Poitiers, France
🇩🇪Praxis Dr. med. Volker Schumann, Berlin, Germany